Literature DB >> 12365026

Childhood cancer survival in Europe and the United States.

Gemma Gatta1, Riccardo Capocaccia, Michel P Coleman, Lynn A Gloeckler Ries, Franco Berrino.   

Abstract

BACKGROUND: Survival rates for most major adult cancers are higher in the United States compared with the survival rates in Europe. The objective of this study was to determine whether transatlantic differences in survival also are present in childhood cancers.
METHODS: The authors analyzed 16,148 European patients and 3476 patients in the United States who were diagnosed with malignant disease at age < 15 years during 1985-1989. The patients were obtained from 34 EUROCARE cancer registries in 17 countries and from 9 SEER registries in the United States. The authors considered the major 14 diagnostic categories of the International Classification of Childhood Cancers. To increase the power of comparisons, they also considered all childhood cancers together. Observed survival was calculated by actuarial methods.
RESULTS: For all cancers combined, northern Europe had the highest 5-year survival rate at 75% (95% confidence interval [95%CI], 72-78%), and Eastern Europe had the lowest survival rate at 55% (95%CI, 52-58%). The survival rate in the United States was roughly comparable to the survival rates in Italy and other Western European countries at 70%. Northern Europe also had highest survival rate for patients with lymphoid leukemias (83%; 95%CI, 78-88%); whereas Germany, Italy, and the other Western European countries had survival rates similar to the average survival rate for patients in the United States (77%; 95%CI, 74-80%). The survival rate was 7-9% lower in Europe compared with the survival rate in United States for patients with neuroblastoma and Wilms tumors and 8% higher for patients with retinoblastoma (all significant). Small, nonsignificant differences were found for patients with osteosarcoma, ependymoma, and medulloblastoma (with a higher survival rate in the United States) and for patients with acute nonlymphocytic leukemia (with a higher survival rate in Europe). Very similar survival rates among the two populations were found for the other cancers.
CONCLUSIONS: Unlike the survival of adults with cancer, the survival of children with cancer in Europe (except Eastern Europe) is very similar to that in the United States. Childhood cancers are generally more responsive to therapy than adult cancers, but these results also may reflect wide accessibility of these treatments for most patients. These results are relevant to the interpretation of differences in adult cancer survival. Copyright 2002 American Cancer Society.

Entities:  

Mesh:

Year:  2002        PMID: 12365026     DOI: 10.1002/cncr.10833

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  53 in total

1.  Osteoblastic and osteolytic human osteosarcomas can be studied with a new xenograft mouse model producing spontaneous metastases.

Authors:  Jun Yuan; Christian Ossendorf; Jan P Szatkowski; James T Bronk; Avudaiappan Maran; Michael Yaszemski; Mark E Bolander; Gobinda Sarkar; Bruno Fuchs
Journal:  Cancer Invest       Date:  2009-05       Impact factor: 2.176

2.  Time trends and prognostic factors for survival from childhood cancer: a report from the Childhood Cancer Registry of Piedmont (Italy).

Authors:  Elisa Dama; Guido Pastore; Maria Luisa Mosso; Milena Maria Maule; Luisa Zuccolo; Corrado Magnani; Franco Merletti
Journal:  Eur J Pediatr       Date:  2006-01-13       Impact factor: 3.183

Review 3.  Risks and diagnosis of coronary artery disease in Hodgkin lymphoma survivors.

Authors:  Serhan Kupeli
Journal:  World J Cardiol       Date:  2014-07-26

4.  Factors influencing time to diagnosis of childhood cancer in Ibadan, Nigeria.

Authors:  B J Brown; B O James; S O Ajayi; O A Ogun; R E Oladokun
Journal:  Afr Health Sci       Date:  2009-12       Impact factor: 0.927

5.  Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors.

Authors:  Alicia M Waters; James M Johnston; Alyssa T Reddy; John Fiveash; Avi Madan-Swain; Kara Kachurak; Asim K Bag; G Yancey Gillespie; James M Markert; Gregory K Friedman
Journal:  Hum Gene Ther Clin Dev       Date:  2017-03       Impact factor: 5.032

Review 6.  Beneficial and harmful effects of anthracyclines in the treatment of childhood acute lymphoblastic leukaemia: a systematic review and meta-analysis.

Authors: 
Journal:  Br J Haematol       Date:  2009-02-22       Impact factor: 6.998

7.  Stereotactic Placement of Intratumoral Catheters for Continuous Infusion Delivery of Herpes Simplex Virus -1 G207 in Pediatric Malignant Supratentorial Brain Tumors.

Authors:  Joshua D Bernstock; Zachary Wright; Asim K Bag; Florian Gessler; George Yancey Gillespie; James M Markert; Gregory K Friedman; James M Johnston
Journal:  World Neurosurg       Date:  2018-11-24       Impact factor: 2.104

8.  Ocular late effects in childhood and adolescent cancer survivors: a report from the childhood cancer survivor study.

Authors:  Kimberly F Whelan; Kayla Stratton; Toana Kawashima; John W Waterbor; Robert P Castleberry; Marilyn Stovall; Charles A Sklar; Roger J Packer; Pauline Mitby; Candice L Aitken; Julie Blatt; Leslie L Robison; Ann C Mertens
Journal:  Pediatr Blood Cancer       Date:  2010-01       Impact factor: 3.167

9.  Geographic and ethnic differences in childhood leukaemia and lymphoma survival: comparisons of Philippine residents, Asian Americans and Caucasians in the United States.

Authors:  M T Redaniel; A Laudico; M R Mirasol-Lumague; A P Alcasabas; D Pulte; H Brenner
Journal:  Br J Cancer       Date:  2010-05-18       Impact factor: 7.640

10.  Population-based survival estimates for childhood cancer in Australia during the period 1997-2006.

Authors:  P D Baade; D R Youlden; P C Valery; T Hassall; L Ward; A C Green; J F Aitken
Journal:  Br J Cancer       Date:  2010-11-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.